Stock Market Today: Natco Pharma share price gained more than 7% to scale 52-week highs on Thursday, The Natco Pharma share price has gained more than 90% year to date. The strong performance in ...

Natco Pharma has decided to price Risdiplam, indicated for the treatment of rare genetic disorder Spinal Muscular Atrophy (SMA), at₹15,900. In an update on the legal proceedings on the ...

Drugmaker Natco Pharma on Tuesday said it intends to launch its generic version of spinal muscular atrophy drug Risdiplam only after and subject to successful clarity from the Appellate Bench of ...

A two-judge bench of Delhi High Court on Wednesday refrained Natco Pharma from launching the generic version of Swiss drugmaker Roche Pharma's patented drug Risdiplam until the hearing on April 2.

The Delhi High Court has denied an injunction request from Swiss pharma major La Hoffman Roche on March 25, in an alleged patent infringement case against Natco Pharma, potentially opening the ...

The Delhi High Court on Monday refused to allow a lawsuit filed by Swiss pharmaceutical company Roche that sought to restrain Indian drug maker Natco Pharma from manufacturing Risdiplam ...